A r t i c l e s
RESULTS

Lentivirally delivered paired-guide RNA system
We constructed a CRISPR pgRNA library such that the genomic sequences between two gRNA-targeting sites could be deleted. First, we tested two approaches to express the pgRNAs in one lentiviral backbone-two U6 promoters driving the two gRNAs separately (U6 2 ) and single U6 promoter driving two gRNAs linked consecutively (U6 1 ) (Fig. 1a) . We compared these two approaches using six pairs of gRNAs that were predicted to delete 2-4.5 kb of the human CSPG4 locus (CSPG4 encodes an integral membrane chondroitin sulfate proteoglycan) (Fig. 1b,c and Supplementary Table 1 ). In the liver cancer cell line Huh7.5 OC, which stably expresses the Cas9 and OCT1 genes 8, 16 , all six pgRNAs in a U6 2 vector produced genomic deletions with the correct sizes, whereas only two pgRNAs in a U6 1 vector produced the correct deletion, and at a much lower efficiency (Fig. 1c) . Five pgRNAs in U6 2 targeting the lncRNA MALAT1 also produced genomic deletions of the correct sizes with high efficiency (Supplementary Fig. 1a ,b and Supplementary Table 2 ). This suggests that U6 2 has superior deletion efficiency, and we therefore adopted it for subsequent experiments. We next investigated whether the posttransduction culture time of lentivirally delivered pgRNAs affected the efficiency of genomic deletion, and observed continued genomic deletion over time that reached a plateau around 15 d post transduction (Fig. 1d) . Similar results were observed when genomic deletions were induced using different pgRNAs targeting CSPG4 (2+2′; Fig. 1b ) or MALAT1 (2+2′; Supplementary Fig. 1a,c,d ). Therefore, culturing library cells for at least 2 weeks post transduction is desirable to allow sufficient time to produce genomic deletions in mammalian cells at a level that is optimal for screening. Genomic sequencing of Genome-scale deletion screening of human long non-coding rNAs using a paired-guide rNA crisPr-cas9 library CRISPR-Cas9 screens have been widely adopted to analyze coding-gene functions, but high-throughput screening of non-coding elements using this method is more challenging because indels caused by a single cut in non-coding regions are unlikely to produce a functional knockout. A high-throughput method to produce deletions of non-coding DNA is needed. We report a highthroughput genomic deletion strategy to screen for functional long non-coding RNAs (lncRNAs) that is based on a lentiviral paired-guide RNA (pgRNA) library. Applying our screening method, we identified 51 lncRNAs that can positively or negatively regulate human cancer cell growth. We validated 9 of 51 lncRNA hits using CRISPR-Cas9-mediated genomic deletion, functional rescue, CRISPR activation or inhibition and gene-expression profiling. Our high-throughput pgRNA genome deletion method will enable rapid identification of functional mammalian non-coding elements.
A r t i c l e s five pgRNAs targeting regions in total (3 pgRNAs targeting CSPG4 and 2 pgRNAs targeting MALAT1) revealed that almost 80% of the deletions at each site were the result of the precise joining of two Cas9 cleavage sites 3 nucleotides (nt) upstream of the protospacer adjacent motifs (PAMs) ( Fig. 1e and Supplementary Fig. 1e ), consistent with previous findings 17 . Taken together, these data indicate that lentivirally delivered pgRNAs are capable of creating large genomic deletions with high efficiency in mammalian cells.
pgRNA library construction and genome-wide lncRNA deletion screen A pgRNA library targeting around 700 human lncRNA genes ( Fig. 2a;  Supplementary Table 3 and Online Methods) with known or putative roles in cancers or other diseases 18 was designed. For each lncRNA target, we first identified all possible 20-nt gRNAs adjacent to the canonical PAM, then filtered gRNAs that were predicted to have low cutting specificity 19 or efficiency 20 (Online Methods and Supplementary Code). We selected gRNA pairs with one unique gRNA as a barcode for each pair (Online Methods) and developed a rapid and accurate method to clone the pgRNAs into a lentiviral expression vector ( Fig. 2b and Supplementary Fig. 2a,b) . Since the two gRNAs in each pair are driven by the same type of U6 promoter and contain identical 3′ scaffold sequences, recombination might occur, which could result in erroneous pgRNA pairing. We tested the recombination rate in both pgRNA library plasmid constructs and chromosomal integrations in cells after transduction, and found that recombination occurred after viral transduction in approximately 7.5% of cells, which is comparable to error rates during oligosynthesis (Supplementary Table 4) . This suggests that recombination should have a negligible effect on pgRNA library screening.
We constructed our pgRNA library in U6 2 at low multiplicity of infection (MOI) into Huh7.5 OC cells that had previously been used for functional screening for coding genes 16 . We cultured the cells for 30 d post transduction to try and maximize the identification of lncRNAs that either positively or negatively affect cell growth or viability. PCRamplified barcode-gRNA regions from the extracted genomic DNA of cells before and after CRISPR screening were subjected to deepsequencing analysis ( Fig. 2c and Supplementary Fig. 2c) . Overall, the read distribution of three independent experimental replicates within each condition showed a high level of correlation ( Fig. 3a and  Supplementary Fig. 3 ). After 30 d of culture, pgRNAs targeting either positive control genes (mostly ribosomal genes) or lncRNAs were depleted compared with negative control pgRNAs (non-targeting pgRNAs or pgRNAs targeting the non-functional adeno-associated virus integration site 1 (AAVS1) loci) (Fig. 3b) , indicative of their effect on cell survival or proliferation. 
A r t i c l e s
We used the MAGeCK algorithm to identify the top hits by comparing samples from day 30 with day-0 controls 21 . MAGeCK evaluates the statistical significance of individual pgRNA abundance changes using a negative binomial (NB) model, and compares the ranks of pgRNAs targeting each lncRNA with a null model of uniform distribution (Online Methods). The output of MAGeCK is a set of negatively (or positively) selected lncRNAs, or lncRNAs whose knockout disrupts (or stimulates) cell proliferation. In total, MAGeCK identified 43 negatively selected and 8 positively selected lncRNAs with statistical significance (false discovery rate < 0.25; Supplementary Table 5) . Gene set enrichment analysis (GSEA) showed that positive control pgRNAs were significantly enriched in the ranked list of negatively selected pgRNAs (Fig. 3c) , as expected given the essential roles of their targets 22 . The top negatively selected genes include two positive control genes: RPL18A, a ribosomal gene, and EZH2, a gene that encodes a member of the Polycomb-group family that has an essential role in the proliferation of liver cancer cells 23 . pgRNAs targeting the promoters and exons of RPL18A and EZH2 were consistently depleted (Fig. 3d,e) . Similarly, 89% of the pgRNAs targeting top-ranked negatively selected lncRNAs were depleted, while 76% of the pgRNAs targeting positively selected lncRNAs were enriched (Fig. 3f,g and Supplementary Fig. 4a,b) . In contrast, the abundances of pgRNAs with non-targeting controls and targeting the AAVS1 loci were similar between control and treatment conditions (Supplementary Fig. 4c ). Intriguingly, 266 pgRNAs targeting 25 intronic regions of essential genes decreased cell viability (Fig. 3d) , possibly as a result of the deletion of regulatory elements or modulation of alternative splicing of the target genes 24, 25 .
Validation of selected lncRNA candidates From the positively or negatively selected lncRNAs with statistical significance, we obtained top-ranked hits whose corresponding pgRNAs were consistently depleted (for negative selection) or enriched (for positive selection) in three independent experimental replicates ( Fig. 3f,g and Supplementary Fig. 5 ). To validate the functions of some of these lncRNAs, we chose two pairs of gRNAs that were present in the original A r t i c l e s screening library and designed up to three additional new pgRNAs for each gene. In addition, three pairs of gRNAs were designed to target the AAVS1 loci to serve as negative controls (Supplementary Table 6 ). All pgRNAs were transduced afresh into Huh7.5 OC cells using a lentiviral backbone carrying CMV-EGFP, and proliferation of cells was quantified based on the percentage change of EGFP-positive cells. Deletion of the promoter of RPL18A, one ribosomal gene that ranked on top of the negative selection list from the screen, strongly decreased cell proliferation, while deletions of the AAVS1 loci had negligible effect on cell growth (Fig. 4a) .
Using the same method, we selected lncRNAs without any overlap with coding genes from the pgRNA library screening for validation. From the initial screen, we chose five negatively selected lncRNAs (AC004463.6, AC095067.1, HM13-AS1, RP11-128M1.1 and RP11-439K3.1) and four positively selected lncRNAs (LINC00176, LINC01087, LINC00882 and LINC00883). We designed pgRNAs to target the promoters or exons of these lncRNAs. For the divergently transcribed pair LINC00882 and LINC00883, which share the same promoter, we designed three additional pgRNAs to target their exons. All five negative-selected lncRNAs were found upon individual deletion to be essential for cell proliferation, and all four positive-selected lncRNAs were confirmed to negatively regulate cell proliferation (Fig. 4b,c and Supplementary Fig. 6a,b) . We further introduced a cDNA clone of LINC00882 into two groups of LINC00882-deleted Huh7.5 OC cells and demonstrated that the ectopic expression of LINC00882 could inhibit cell proliferation (Supplementary Fig. 6c,d ). Some pgRNAs, such as RP11-439K3.1_p3 and RP11-439K3.1_p4, did not produce distinct phenotypes (Fig. 4b) . P values were calculated using Student's t-test and corrected for multiple comparison using Benjamini-Hochberg procedure, *P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant. Fig. 6e ). To further validate candidate genes, we used a CRISPR-inhibitor (CRISPRi) method 26 that can reduce the transcription of the targeted gene. Out of the five negatively selected lncRNAs, we were able to successfully decrease the expression of three (AC004463.6, RP11-439K3.1 and AC095067.1) using CRISPRi, and all significantly decreased cell proliferation (Fig. 4d) . We also carried out cell lethality assays on lines with deletion on the five negatively selected lncRNAs and on the CRISPRi lines (transcription of lncRNAs repressed), and found all five lncRNAs to be essential for cell viability (Supplementary Fig. 7 and Supplementary Table 7 ). For positively selected gene candidates LINC01087 and LINC00882, we used a CRISPR-activator (CRISPRa) method 27 to upregulate their transcription, and found both lncRNAs to be lethal when overexpressed (Supplementary Fig. 8 and Supplementary  Table 7) . Therefore, the CRISPR-Cas9 screen strategy from genomic deletion works well for both negatively and positively selected lncRNAs with high efficiency and reliability. For both CRISPR screening and candidate validation, we introduced paired gRNAs into cells. It is possible that the phenotypic changes we observed were due to the effect of one gRNA-mediated . P values were calculated using Student's t-test and corrected for multiple comparisons using the BenjaminiHochberg procedure. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant.
A r t i c l e s genomic deletions (Supplementary
double-strand break (DSB) instead of pgRNAs-mediated genomic deletion. To exclude this possibility, we compared the effects of pgRNAs targeting AC004463.6 and AC095067.1 with the effects of introducing only one of their corresponding gRNAs. Only pgRNAs significantly affected cell proliferation in both cases, while none of the single gRNAs targeting introns or exons altered cell survival ( Fig. 4e and Supplementary Fig. 6f ). This suggests that, at least for these two lncRNAs, pgRNA-mediated genomic deletion is required to generate functional knockout, an effect unlikely to be achieved through indels created by single gRNAs.
Functional analysis of validated lncRNAs
We next sought to investigate the potential functions of LINC01087, one of the top positively selected lncRNAs in the screen. We knocked out LINC01087 with three different pgRNAs and observed similar changes in gene expression patterns from RNA-seq ( Fig. 5a and Supplementary Fig. 9a−c) . Knocking out LINC01087 did not affect the expression of neighboring protein-coding genes ( Supplementary  Fig. 9d ), but instead upregulated a set of genes associated with liver cancer. The upregulated genes included FOS and FOSB (Fig. 5b) , which encode members of the FOS gene family and AP-1 transcription factor complex 28 ; liver-cancer-upregulated genes; targets of the hepatocellular oncogenic transcription factor HNF4α 29 ; and genes involved in retinol metabolism (Fig. 5c) .
We also evaluated the predicted functions of our top 15 lncRNA hits using "guilt by association," a computational approach for inferring lncRNA function from the enriched functions of co-expressed coding genes 30 . We analyzed the expressions of genes and lncRNAs in five different cancers (liver, prostate, ovarian, lung cancer and glioblastoma multiforme) using data sets from the Cancer Cell Line Encyclopedia (CCLE) and The Cancer Genome Atlas (TCGA), respectively 18, 31 (Online Methods). Many of the genes that were co-expressed with negatively selected lncRNAs were enriched in essential processes such as RNA metabolism and cell cycle, whereas genes correlated with positively selected lncRNAs were enriched in the negative regulation of these essential processes ( Fig. 5d,e; Supplementary Fig. 10 and Supplementary Table 8 ). This is consistent with the finding that knockout of these negatively (or positively) selected lncRNAs disrupts (or enhances) cell proliferation and viability. One of the negatively selected lncRNAs, AC004463.6, is significantly overexpressed in liver cancer and metastatic prostate cancer (Fig. 5f) , and five out of the seven negatively selected lncRNAs in Huh7.5 are significantly overexpressed in metastatic prostate cancers (Supplementary Fig. 11 ). In addition, two of the five validated negatively selected lncRNAs, AC004463.6 and RP11-439K3.1, were confirmed to be essential in 22RV1, a relapsed prostate cancer cell line 32 ( Supplementary  Fig. 12 ). These results suggest that the lncRNAs selected in liver cancer cell lines may also function in other cancer types.
lncRNA screening in HeLa cells
To assess the functions of lncRNAs in a different cell type, we screened HeLa cells using our lncRNA library (Supplementary Table 9 ). Positive control pgRNAs and genes were negatively selected, an indication that our screen works well in HeLa cells as well ( Fig. 5g and  Supplementary Fig. 13) . A further comparison of the screens done in Huh7.5 and HeLa cells revealed different roles for distinct lncRNAs in these two cell types (Fig. 5g) . Of the top negatively selected and validated lncRNAs in Huh7.5, we tested five lncRNAs in HeLa, including two that seemed to be essential (AC095067.1 and RP11-128M1.1) and three that appeared to be non-essential (HM13-AS1, AC004463.6 and RP11- 439K3.1, Fig. 5h ) in the HeLa cell screen. Indeed, knocking out two essential lncRNAs reduced cell proliferation, and knocking out two of the three non-essential lncRNAs had no effect on cell proliferation. Our screen missed AC004463.6, which was found to be essential in HeLa through individual validation, an indication that the current lncRNA pgRNA library still has space for improvement.
DISCUSSION
The vast majority of all mammalian genomes comprise non-coding regions, many of which have important regulatory roles. Functional analyses of non-coding regions have been challenging, and an effective screening strategy for non-coding regions based on genomic deletion was, until now, lacking. We have established a genome deletion screening method using CRISPR-Cas9 screens with paired gRNAs in mammalian cells. Using this method, we screened approximately 700 human lncRNAs and identified lncRNAs that have oncogenic or tumor suppressor activities in cancer cells. Orthogonal validation of top hits using individual CRISPR-Cas9 knockout, CRISPR inhibition and activation, gene expression profiling and expression correlation analysis confirmed the findings of our screens and showed that our method has a high level of fidelity and specificity.
There are potential limitations to our lncRNA screening strategy. First, deleting lncRNAs may also affect other proximal functional elements, including enhancers and microRNAs. It is desirable to avoid designing pgRNAs that overlap with other functional elements where possible, to examine hits for potential enhancer function and to validate screening results using orthogonal technologies. Our screening approach cannot reveal mechanisms of lncRNA action 30 , so a detailed investigation is needed to further understand the functions of identified lncRNAs. More than 30% of the lncRNAs are located in the introns of other coding genes with diverse biological functions 33 . Further characterization of these lncRNAs is challenging, as disrupting introns may perturb splicing or other regulatory elements and have deleterious effects on cell proliferation (for example, the intron-targeting pgRNAs in Fig. 3d) . Finally, pgRNA orientation seems to have negligible effects on the knockout phenotype, but the number of pgRNAs per lncRNA is crucial to reduce the false negative rate of the screens (Supplementary Figs. 14 and 15a) . Not all of the positive controls were identified in our screen, which shows that the sensitivity of the screen needs improvement. As the deletion frequencies for pgRNAs vary ( Fig. 1d and Supplementary Fig. 1 ), a sufficient number of pgRNAs (preferably >20) targeting each lncRNA is desirable to reduce the false negative rate. Although our CRISPR pgRNA library might theoretically cause incorrect pgRNA assembly due to paired gRNA recombination in the lentiviral packaging and integration step (owing to the sequence similarity of two U6 promoters and two repeats of gRNA scaffold sequences), we found that our screen was unaffected, a result of a low recombination rate. We could further reduce the potential lentiviral recombination rate by using different types of U6 promoters (of human and murine origins) 34 and alternative sgRNA scaffold sequences.
Our approach to screening for function of the non-coding genome could be applied to investigate phenotypic changes of interest other than growth by incorporating a reporter system. Finally, our pairedguide RNA screening strategy could be more broadly applied to study other non-coding sequences including microRNAs, cis elements and other currently uncategorized elements.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. Plasmid construction. The lentiviral pgRNA-expressing vector was constructed by cloning the human U6 promoter, ccdB cassette and gRNA scaffold into pLL3.7 (Addgene, Inc.) by replacing its original U6 promoter 8 . The scaffold-linker-U6 fragment was cloned into pEASY-Blunt plasmid (TransGen Biotech).
A r t i c l e s
lncRNA selection. lncRNA targets in cancer. lncRNA targets consist of known cancer-related lncRNAs and lncRNAs that are differentially expressed in tumors. We used lncRNA expression estimation from a recent study repurposing exon array probes to lncRNAs 18 and used the Limma algorithm 36 to identify overexpressed lncRNAs in cancer. In total, 671 lncRNAs were selected and up to 20 pgRNAs were designed for each target. Among the 20 pairs, 10 target the promoter regions, and the other 10 target promoters plus exons.
Positive controls. Positive control genes consist of 20 genes, including 17 ribosomal genes and 3 cancer-related genes, FOXA1, HOXB13 and EZH2. We designed 100 pairs for each positive control gene, including 20 targeting promoters (the distance between two gRNAs in each pair is between 200 bp and 5 kb), and 80 targeting promoters plus exons. Among the 80 pairs targeting promoters plus gene bodies, 60 were designed such that their gRNA orientations are consistent with gene orientations. This is because gRNAs with the same orientation of their targeting genes have a better knockout effect than gRNAs with a distinct orientation 37 . The rest 20 pairs were designed to have at least one different orientation with the targeting gene.
Negative controls. We designed 500 pgRNAs of negative controls with three different types. The first type of negative control (100 pairs) consists of pgRNAs that do not target any loci in the human genome. These pgRNAs will be constructed directly from existing non-target control gRNAs from GeCKO v2 library 38 . The second type of control (100 pairs) consists of pgRNAs targeting the AAVS1 region, which is a non-essential region in genome and is frequently used in CRISPR studies for efficiency test. The third type of negative control (300 pairs) consists of pgRNAs targeting the introns of positive control genes. gRNA scanning and filtering. After the regions were selected, we identified all possible gRNAs by searching the PAM motif in the genome sequence. We only kept the gRNAs if (1) their sequences are uniquely mapped to the intended loci, (2) have at least 2 mismatches to any other loci of the genome, and (3) their predicted efficiency scores are above 0.3. The efficiency score prediction was calculated from our recently published machine-learning model 20 . For gRNA pairs targeting lncRNAs, we further required (4) the GC content to be between 0.2 and 0.9, and (5) that the gRNAs not include the UUUU/TTTT polymer. This is because gRNAs with extreme GC content or with UUUU/ TTTT sequence have been shown to have lower cleavage efficiency 26, 37 .
pgRNA design. For all sgRNAs targeting each lncRNA or positive control gene, we first enumerated all possible pgRNAs and then kept pairs that satisfy all of the following conditions:
1. Include one sgRNA before TSS and one after TSS; 2. Do not overlap with any exons of coding regions (for lncRNA targets); 3. Have the same sgRNA orientation as target lncRNA or gene; 4. Are at least 5 kb away from the promoters of coding regions (for lncRNA targets);
5. Are at least 50 bp away from the exon-intron boundary of coding genes (for lncRNAs located inside the introns of another coding gene).
For each lncRNA or gene, if there are not enough pgRNAs, we also included pgRNAs that (1) do not cross over TSS or (2) have different orientation compared with targeted lncRNA or gene. For all pgRNAs that pass the filter mentioned above, we next sought to identify desired number of pgRNAs with barcode (Fig. 2) , and require the barcode gRNA is used only once in the library. Note that randomly assigning one of the two gRNAs as the barcode may result in some pgRNAs with no available barcode (see Supplementary Text 1) . Alternatively, we designed an iterative "greedy" algorithm to identify possible pgRNAs and their barcodes, and proved that this algorithm can identify the optimal number of pgRNAs with barcodes (see Supplementary Text 1) .
The pgRNA design algorithm, "pgRNADesign", is open-source and freely available at https://bitbucket.org/liulab/pgrnadesign. Besides the pgRNA design and barcode assignment, pgRNADesign further allows users to specify a list of "blackout" regions. Once specified, pgRNADesign will avoid designing pgRNAs that overlap with these blackout regions.
Construction of the CRISPR-Cas9 pgRNA library. We created a library targeting 671 lncRNAs with 12,472 pairs of gRNAs as mentioned above (Supplementary Table 3 ). The 137-nt oligonucleotides containing each pairs of pgRNA-coding sequences were designed (Supplementary Table 10 ) and synthesized (CustomArray, Inc.). Then, primers targeting the flanking sequences of oligonucleotides were used for the amplification to create 60-bp homologies with BsmBI digested pgRNA-expressing backbone. The amplified DNA products were ligated into the lentiviral vector using Gibson cloning method 39 and were transformed into Trans1-T1 competent cells (TransGen, Biotech) to obtain the plasmids. Plasmids were then digested by BsmBI and ligated with BsmBI-digested scaffold-linker-U6 fragment (Supplementary Fig. 2b) , and the ligation mixture was transformed into Trans1-T1 competent cells (TransGen, Biotech) to obtain the final library plasmids (see Supplementary Text 2 for sequences). The lentivirus of the pgRNA library was produced by co-transfection of library plasmids with two viral packaging plasmids pVSVG and pR8.74 (Addgene, Inc.) into HEK293T cells using the X-tremeGENE HP DNA transfection reagent (Roche). Huh7.5 OC cell library was constructed through transduction of low MOI (~0.3) virus, followed by FACS for EGFP + cells, 72 h after infection.
Recombination rate calculation. The recombination rates were calculated in both plasmid constructs and chromosomal integrations in cells after transduction. For plasmid, we amplified the entire pgRNA sequence from the library plasmid as the template. For chromosomal integrations in cells, the pgRNA sequence was amplified from the genome of library cells as the template. The PCR products were then cloned into vectors for sequencing analysis. 80 and 120 clones were randomly selected from the plasmids and the cell libraries for sequencing, respectively.
CRISPR-Cas9 pgRNA library screening. A total of 1.2 × 10 7 pgRNA library cells were plated onto 150 mm Petri dishes and three replicates were arranged. The library cells of control group were collected for genomic DNA extraction and that of experimental group were incubated for one month. Then genomic DNA of experimental group was also extracted, followed by PCR amplification of the barcode gRNA-coding regions and deep-sequencing analysis.
Identification of candidate pgRNA sequences and data analysis. The genomic DNA of every replicate was isolated from 4 × 10 6 cells using the DNeasy Blood and Tissue kit (Qiagen). gRNA-coding regions integrated into the chromosomes were then PCR amplified (TransTaq DNA Polymerase High Fidelity; TransGen) with 28 cycles of reaction using primers targeting U6 promoter and the linker between two gRNAs of each pair ( Supplementary Fig. 2 and Supplementary Table 11) . In every tube, 0.6 µg of genomic DNA was used as the template and 20 PCR reactions were performed for each replicate. The PCR products of each replicate were pooled together and purified with DNA Clean & Concentrator-25 (Zymo Research Corporation), followed by deep-sequencing analysis (Illumina HiSeq 2500).
